• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

NuGen launches needle-free insulin delivery device in Canada

December 6, 2024 By Sean Whooley

NuGen Medical needle-free InsuJet device
The InsuJet needle-free device. [Image from the NuGen Medical website]
NuGen Medical Devices announced recently that it launched its InsuJet needle-free insulin delivery device in Canada.

The company initiated its launch on Nov. 15 — the day after World Diabetes Day. It received an initial order for 2,500, then a second order for 750 units of InsuJet starter kits and consumables. That represents revenue of $670,000, according to a news release.

InsuJet — approved for sale in 42 countries — uses a simple, powerful spring-loaded mechanism. Following pressure build-up, the device releases the drug as a fine jet stream of liquid, fast enough to penetrate the skin through a microscopic entrance. It dispenses the drug safely and evenly in less than one-tenth of a second with virtually no pain and no mark on the skin.

NuGen said leading pharmacy networks across Canada have InsuJet supply through major distributors. Those include McKesson Canada, Khol & Frisch Distributors, Imperial Distributors and UniPharm Distribution. They provide all 12,000 pharmacies across Canada access to InsuJet, the company said.

“We are extremely excited to be taking NuGen to a new level of distribution globally to manage diabetes and the delivery of insulin needle-free. As the birthplace of Insulin, Canada represents another great place for us with the rest of the world to follow with InsuJet approved for use in 42 countries,” said Karen Dunlap, NuGen interim CEO. “We are combining our technical IP experience with our distributor’s commercial and clinical strategies to support this strong growth.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations Tagged With: NuGen

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS